KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity (2017 - 2025)

Historic Common Equity for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$4.1 million.

  • Aquestive Therapeutics' Common Equity rose 9095.33% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 9095.33%. This contributed to the annual value of -$60.2 million for FY2024, which is 4350.86% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Common Equity of -$4.1 million as of Q3 2025, which was up 9095.33% from -$72.6 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Common Equity high stood at -$4.1 million for Q3 2025, and its period low was -$118.6 million during Q4 2022.
  • Over the past 5 years, Aquestive Therapeutics' median Common Equity value was -$72.6 million (recorded in 2025), while the average stood at -$73.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 15139.8% in 2021, then surged by 9095.33% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Common Equity (Quarter) stood at -$82.1 million in 2021, then plummeted by 44.34% to -$118.6 million in 2022, then increased by 10.18% to -$106.5 million in 2023, then surged by 43.51% to -$60.2 million in 2024, then soared by 93.17% to -$4.1 million in 2025.
  • Its Common Equity stands at -$4.1 million for Q3 2025, versus -$72.6 million for Q2 2025 and -$60.9 million for Q1 2025.